189 related articles for article (PubMed ID: 35938863)
21. CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.
Pacenta HL; Laetsch TW; John S
Paediatr Drugs; 2020 Feb; 22(1):1-11. PubMed ID: 31749131
[TBL] [Abstract][Full Text] [Related]
22. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ; Tam CS; Borchmann P; Worel N; McGuirk JP; Holte H; Waller EK; Jaglowski S; Bishop MR; Damon LE; Foley SR; Westin JR; Fleury I; Ho PJ; Mielke S; Teshima T; Janakiram M; Hsu JM; Izutsu K; Kersten MJ; Ghosh M; Wagner-Johnston N; Kato K; Corradini P; Martinez-Prieto M; Han X; Tiwari R; Salles G; Maziarz RT
Lancet Oncol; 2021 Oct; 22(10):1403-1415. PubMed ID: 34516954
[TBL] [Abstract][Full Text] [Related]
23. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.
Vairy S; Garcia JL; Teira P; Bittencourt H
Drug Des Devel Ther; 2018; 12():3885-3898. PubMed ID: 30518999
[TBL] [Abstract][Full Text] [Related]
24. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
Ghorashian S; Jacoby E; De Moerloose B; Rives S; Bonney D; Shenton G; Bader P; Bodmer N; Quintana AM; Herrero B; Algeri M; Locatelli F; Vettenranta K; Gonzalez B; Attarbaschi A; Harris S; Bourquin JP; Baruchel A
Lancet Haematol; 2022 Oct; 9(10):e766-e775. PubMed ID: 36084658
[TBL] [Abstract][Full Text] [Related]
25. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.
Hucks G; Rheingold SR
Blood Cancer J; 2019 Jan; 9(2):10. PubMed ID: 30670684
[TBL] [Abstract][Full Text] [Related]
26. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
[TBL] [Abstract][Full Text] [Related]
27. Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
Galletta TJ; Rubinstein JD; Krupski C; Nelson AS; Khoury R; Dandoy CE; Davies SM; Phillips CL
Pediatr Blood Cancer; 2023 May; 70(5):e30271. PubMed ID: 36815392
[TBL] [Abstract][Full Text] [Related]
28. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
29. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
[TBL] [Abstract][Full Text] [Related]
30. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
[TBL] [Abstract][Full Text] [Related]
31. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
Liu Y; Chen X; Han W; Zhang Y
Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276
[TBL] [Abstract][Full Text] [Related]
32. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
33. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Oporto Espuelas M; Burridge S; Kirkwood AA; Bonney D; Watts K; Shenton G; Jalowiec KA; O'Reilly MA; Roddie C; Castleton A; Clesham K; Nicholson E; Alajangi R; Prabhu S; George L; Uttenthal B; Gabelli M; Neill L; Besley C; Chaganti S; Wynn RF; Bartram J; Chiesa R; Lucchini G; Pavasovic V; Rao A; Rao K; Silva J; Samarasinghe S; Vora A; Clark P; Cummins M; Marks DI; Amrolia P; Hough R; Ghorashian S
Blood Cancer J; 2024 Apr; 14(1):66. PubMed ID: 38622139
[TBL] [Abstract][Full Text] [Related]
34. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
Leahy AB; Devine KJ; Li Y; Liu H; Myers R; DiNofia A; Wray L; Rheingold SR; Callahan C; Baniewicz D; Patino M; Newman H; Hunger SP; Grupp SA; Barrett DM; Maude SL
Blood; 2022 Apr; 139(14):2173-2185. PubMed ID: 34871373
[TBL] [Abstract][Full Text] [Related]
35. Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.
Fabrizio VA; Curran KJ
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101305. PubMed ID: 34625231
[TBL] [Abstract][Full Text] [Related]
36. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
[TBL] [Abstract][Full Text] [Related]
37. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
38. Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection.
Hall EM; Yin DE; Goyal RK; Ahmed AA; Mitchell GS; St Peter SD; Flatt TG; Ahmed IA; Li W; Hendrickson RJ; August KJ; Myers GD
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472856
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.
Hiramatsu H; Adachi S; Umeda K; Kato I; Eldjerou L; Agostinho AC; Natsume K; Tokushige K; Watanabe Y; Grupp SA
Int J Hematol; 2020 Feb; 111(2):303-310. PubMed ID: 31709501
[TBL] [Abstract][Full Text] [Related]
40. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
